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Liposome is one of the most successful drug delivery systems applying nanotechnology to
potentiate the therapeutic efficacy and reduce toxicities of conventional medicines. Since
the first doxorubicin-loaded liposome reached the market, numerous researches have been
carried out to develop new liposomal formulations over the past decade and have given
birth to a series of commercial products. Therapeutic agents, most of which are anti-cancer
drugs, are encapsulated in the aqueous core or lipid bilayers of liposomes to improve their
delivery to the targeted tissue. There are several liposomal formulations, such as EndoTAG-
1 (paclitaxel-loaded cationic liposomes), Lipoplatin (cisplatin-loaded long circulating lipo-
somes) and Stimuvax (a cancer vaccine), showing promising therapeutic value in clinical
studies. Besides, new designs including environmentally sensitive liposomes, liposomal
drug combinations and liposomal vaccines are now tested in clinical trials.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction Liposomes are round bubbles consisting of an aqueousThe efficacy of therapeutic molecules is often limited by the
insufficient delivery, accumulation in target tissues or unde-
sirable side effects even severe toxicities in healthy organs. In
recent years, nanoparticles such as polymeric micelles [1,2],
liposomes [3e5] and conjugated nanoparticles [6e8] have
inspired the drug development. Among these delivery sys-
tems, liposomes appear promising because of their biocom-
patible composition as well as superior efficacy, especially the
significant improvement in drug circulation and bio-
distribution materialized by PEGylation [9].aceutics, School of Pha
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ang Pharmaceutical Univcore encapsulated by natural or synthetic phospholipids. This
structure turns liposomes into ideal drug carriers, since hy-
drophilic drugs tend to be entrapped in the core; while hy-
drophobic ones will be entrapped within the lipid bilayers.
The encapsulation is partially dependent on the partition co-
efficient or LogP of a certain drug [10]. Prepared by different
methods, liposomes vary with size, lamellarity and surface
charge. Generally, liposomes can be classified as unilamellar
or multilamellar. Unilamellar liposomes are further divided
into small size (SUV, 50e100 nm) or large size (LUV,
100e250 nm). SUV and LUV are both composed of a single lipidrmaceutical Sciences, Peking University, No. 38 Xueyuan Road,
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Table 1 e Approved liposomal formulations.
Drug Product
name
Type Lipid composition Route of
administration
Approved treatment Reference
Amphotericin B Ambisome Liposome HSPC, DSPG and
cholesterol
Intravenous Sever fungal infections [3]
Doxorubicin Myocet Liposome EPC and cholesterol Intravenous Metastatic breast cancer [11,12]
Doxil PEGylated
liposome
HSPC, cholesterol and
DSPE-PEG2000
Intravenous Kaposi’s sarcoma, ovarian
and breast cancer
[5,13]
Lipo-dox PEGylated
liposome
DSPC, cholesterol and
DSPE-PEG2000
Intravenous Kaposi’s sarcoma, ovarian
and breast cancer
[14]
Daunorubicin DaunoXome Liposome DSPC and cholesterol Intravenous Blood cancer [4,15]
Verteporfin Visudyne Liposome EPG and DMPC Intravenous Age-related molecular
degeneration
[16e18]
Cytarabine Depocyt Liposome DOPC, DPPG, cholesterol
and triolein
Spinal Neoplastic meningitis and
lymphomatous meningitis
[19]
Morphine
sulfate
DepoDur Liposome DOPC, DPPG, cholesterol
and triolein
Epidural Pain [20,21]
Vincristine
sulfate
Marqibo Liposome Egg sphingomyelin
and cholesterol
Intravenous Acute lymphoblastic leukemia [22,23]
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hydrophilic drugs; while multilamellar liposomes (MLV),
usually with a diameter of 1e5 mm, are composed of several
lipid bilayers and a limited aqueous space, thus suitable for
loading hydrophobic drugs.
From the first liposomal pharmaceutical product-Doxil
approved in 1995 to the latest Marqibo in 2012, there are now
a few successful liposomal formulations (Table 1).Most of themTable 2 e Liposomal formulations in clinical trials.
Drug Product
name
Lipid composition
adm
Paclitaxel LEP-ETU DOPC, cholesterol and cardiolipin In
EndoTAG-1 DOTAP and DOPC In
Doxorubicin ThermoDox DPPC, MSPC and DSPE-PEG2000 In
Cisplatin and
its analog
SPI-077 HSPC, cholesterol and DSPE-mPEG In
Lipoplatin SPC, DPPG, cholesterol and
DSPE-mPEG
In
Aroplatin DMPC and DMPG In
in
Mitoxantrone LEM-ETU DOPC, cholesterol and cardiolipin In
Topotecan INX-0076 Egg sphingomyelin and cholesterol In
Vinorelbine INX-0125 Egg sphingomyelin and cholesterol In
Lurtotecan OSI-211 HSPC and cholesterol In
Amikacin Arikace DPPC and cholesterol In
ae
BLP25 lipopeptide Stimuvax Monophosphoryl lipid A,
cholesterol, DMPG and DPPC
Su
All-trans retinoic
acid
Atragen DMPC and soybean oil In
Annamycin Liposome-
annamycin
DSPC, DSPG and tween In
Cytarabine and
daunorubicin
CPX-351 DSPC, DSPG and cholesterol In
Irinotecan HCL
and floxuridine
CPX-1 DSPC, DSPG and cholesterol Inhave to be administrated intravenously due to the degradation
of lipids in the gastrointestinal tract. However, some recent
formulations such as Arikace (see Table 2) can be subcutane-
ously injected or inhaled as aerosols. Apart from a broadened
range of drugs being investigated for liposomal formulations,
new strategies such as environmental sensitivity and combi-
nation therapy have been applied to the development process
to achieve better efficacy. Moreover, liposomes could beRoute of
inistration
Treatment under
investigation
Trial
phase
Reference
travenous Ovarian, breast and lung cancers I [32,33]
travenous Anti-angiogenesis, breast and
pancreatic caners
II [34]
travenous Non-resectable hepatocellular
carcinoma
III [35,36]
travenous Lung, head and neck cancers I/II [37,38]
travenous Pancreatic cancer, head and
neck cancer, mesothelioma,
breast cancer, gastric cancer
and non-small-cell lung cancer.
III [39,40]
trapleural/
travenous
Malignant pleural mesothelioma
and advanced colorectal
carcinoma
II [41,42]
travenous Leukemia, breast, stomach, liver
and ovarian cancers
I [43,44]
travenous Advanced solid tumors I [9]
travenous Breast, colon and lung cancers I [9,45]
travenous Ovarian, head and neck cancers II [46,47]
haled as
rosol
Lung infection III [48,49]
bcutaneous Non-small-cell lung carcinoma III [50]
travenous Advanced renal cell carcinoma I/II [51]
travenous Breast cancer I/II [52,53]
travenous Acute myeloid leukemia II [54]
travenous Colorectal cancer II [55,56]
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as vaccines. This reviewwill introduce the approved liposomal
products, while focus more on the species under clinical trials
and new tendencies in their development.2. Development of liposomal drugs: a typical
example of doxorubicin
Doxorubicin, a kind of anthracyclines, is a potent and broad-
spectrum anti-cancer drug and has been used as a “first-
line” medicine in cancer therapy [24]. Two main mechanisms
of action are involved for the drug: (1) it inhibits DNA and RNA
synthesis by inserting in base pairs of DNA strands, thus
preventing the replication and transcription in rapidly-
growing cancer cells; (2) it inhibits the enzyme topoisomer-
ase II, which is an additional way for blocking DNA tran-
scription and replication. However, the positively charged
doxorubicin is also of high affinity to negatively charged car-
diolipin, which is abundant in heart tissue [25]. This damage
results in the dangerous cumulative dose-dependent car-
diotoxicity (i.e. irreversible congestive failure), which consid-
erably limits the tolerable dose range of doxorubicin. Other
side effects of doxorubicin include severe myelosuppression,
nausea and vomiting and mucocutaneous toxicities [5].
Therefore, liposomal formulation is proposed to overcome
these toxicities. Initially, liposomal doxorubicin was prepared
to be negatively charged, medium-size oligolamellar lipo-
somes, in which the drug was passively entrapped by the lipid
hydration method [26]. However, this formulation failed in
following clinical trials mainly due to the rapid drug release
and clearance by reticuloendothelial system in vivo. “Remote
loading” was then used to improve the drug loading efficiency
and formulation stability, bringing about Myocet and Doxil in
which doxorubicinwas loaded by a pH or ammonium gradient,
respectively. The morphology and structure of Doxil is shown
in Fig. 1. A major advancement of Doxil over Myocet is the
coating with PEG, which significantly improves its pharmaco-
kinetic profile. So in a pharmacokinetic study of doxorubicin-
loaded liposomes, free doxorubicin had an elimination half-
life of 0.2 h and an area under the plasma concen-
trationetime curve (AUC) of 3.81 mg h/ml, comparedwith 2e3 h
and 46 mg h/ml for Myocet and with a further increase to
41e70 h and 902 mg h/ml for Doxil [27]. Both Myocet and Doxil
significantly reduce the toxic effects of doxorubicin. In a Phase
III comparison of free doxorubicin with Myocet, patientsFig. 1 e (A) Morphology of Doxil by cryo-TEM.treated with Myocet had low incidence of cardiac events (13%
vs. 29%), mucositis/stomatitis (8.6% vs. 11.9%), and nausea/
vomiting (12.3% vs. 20.3%) [28]. Similar results were found in
another Phase III trial of Doxil, in which the reduction of car-
diotoxicity (3.9% vs. 18.8%), neutropenia (4% vs. 10%), vomiting
(19% vs. 31%), and alopecia (20% vs. 66%) were found [29].
However, equivalent survival rates between liposomes and
free drugs were found in these studies, suggesting the advan-
tage of Myocet and Doxil lay only in the reduction of toxicities.
Lipo-dox is the third approved liposomal formulation for
doxorubicin. Themajor improvement is the application of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), a kind of lipid
consists of saturated fatty acids and has high phase-transition
temperature (Tm). The high Tm makes Lipo-dox less likely to
leak drugs and thus more stable. Since Lipo-dox is also
PEGylated, significantly long in vivo circulation is found, as its
half-life is about 65 h [30]. However, no further improvement
in therapeutic efficacy is achieved by Lipo-dox. When inves-
tigated in patients with metastatic breast cancer, Lipo-dox
induced the overall response rate of 41.2%, the median time
to disease progression of 163 days, and themedian duration of
response in responding patients of 286 days, all of which were
similar to those of Doxil [31]. Moreover, the major side effects
of Lipo-dox were stomatitis and skin toxicity, which were also
found during Doxil treatment [5,29]. In fact, although the
cardiotoxicity is reduced by PEGylation, the long circulation
time often results in skin toxicity referred as Palmar Plantar
Erythrodysthesia (PPE) [5], which is a drawback of PEGylated
doxorubicin-loaded liposomes and remains to be overcome.3. Clinical studies of liposomal formulations
Some liposomal formulations currently under clinical trials are
summarized in Table 2. Model drugs range from conventional
chemotherapeutic agents to lipopeptide. But the application of
newly developed liposomes is more and more focused on can-
cer therapy. In addition, synthetic lipids are more widely used.
3.1. Paclitaxel liposomes
Paclitaxel is a potent anti-cancer drug used in various tumors,
including ovarian, breast and non-small-cell lung carcinoma
[57]. Due to thepoorwater solubility ofpaclitaxel, the surfactant
Cremophor EL is used in its marketed product Taxol. However,
Cremophor EL increased the toxicity and led to hypersensitivity(B) Illustration of the structure of Doxil [5].
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formulation of paclitaxel, was developed to eliminate the se-
vere toxicity of Taxol. In a Phase I pharmacokinetic/pharma-
codynamic study, themaximum tolerated dose of LEP-ETUwas
325 mg/m2, which was higher than the typical dose range of
135e200 mg/m2 permitted with Taxol [33]. Neutropenia was
found to be the major side effect of LEP-ETU, but it was not
worse than that observed with Taxol treatment [59]. Therefore,
LEP-ETU achieved higher doses of paclitaxel treatment with
neither the allergic reaction nor new severe toxicities.
EndoTAG-1 is another liposomal formation of paclitaxel.
The cationic lipid, DOTAP, is firstly used for constructing
liposomal paclitaxel. In addition to the anti-tumor effect of
paclitaxel, EndoTAG-1 also inhibits tumor vasculature, which
is possibly due to the vascular targeting by cationic liposomes
[60]. In both orthotopic pancreatic cancer and subcutaneous
Lewis lung carcinoma models, EndoTAG-1 was delivered pri-
marily to tumor epithelium, whereas Taxol was distributed in
the interstitial region. There was a synergetic effect between
EndoTAG-1 and cisplatin chemotherapy, and the metastasis
of pancreatic cancer could be inhibited by the combinational
therapy of EndoTAG-1 and gemcitabine [61].
3.2. Cisplatin liposomes
Cisplatin is another widely used anti-cancer drug, which in-
ducesDNAlesionsandmitochondrial apoptosis.However, often
observed toxicities including nephrotoxicity, neurotoxicity and
ototoxicity [62] demand new formulations to be developed to
reduce toxicitiesandpotentiateefficacy.SPI-077 is the liposomal
cisplatin with long circulating profile. In a Lewis lung tumor
model, SPI-077 achieved a 28-fold higher tumor AUC than
cisplatin, while a 4-fold reduction of cisplatin delivered to kid-
neys [63].Moreover, SPI-077exhibited theequivalent anti-tumor
efficacyat onlyhalf thedoseof cisplatin.However, ina following
Phase IeII study, SPI-077 did not show appreciable efficacy for
patients with inoperable head and neck cancer [38].
Lipoplatin is an alternative liposomal formulation of
cisplatin. Similar to SPI-077, Lipoplatin also reduces
cisplatin-induced toxicities [64]. Besides, Lipoplatin is effi-
cacious against several tumors, such as breast cancer, non-
small-cell lung cancer, pancreatic cancer and head and neck
cancer. In a recent Phase II study, patients with metastatic
breast cancer were treated with Lipoplatin and vinorelbine
in combination. The objective response rate and median
survival time were 53.1% and 22 months, respectively, while
the side effects observed were acceptable [65]. Therefore,
this regimen was proposed as a first-line therapy for met-
astatic breast cancer. In another Phase III study, 202 pa-
tients with non-small-cell lung carcinoma were treated with
paclitaxel combined with Lipoplatin or cisplatin. It was
found the response rate was 59.22% of Lipoplatin group
versus 42.42% of cisplatin group. After 18 months, the
number of surviving patients was double with Lipoplatin
treatment versus cisplatin treatment [66].
Aroplatin encapsulates cis-bis-neodecanoato-trans-R,R-
1,2-diaminocyclohexane platinum (II) (L-NDDP), a structural
analog of oxaliplatin. It has been investigated in patients with
malignant pleuralmesothelioma in a Phase II study. Following
the intrapleural administration, a response rate of 42% and amedian survival time of 11.2 months were observed [41]. In
another Phase II study concerning advanced colorectal cancer,
both anti-tumor efficacy and tolerable toxicity were found
after the intravenous administration of Aroplatin [42].
3.3. New tendencies in the development of liposomal
formulation
3.3.1. Environmentally sensitive liposomes in cancer therapy
High efficiency of drug release from liposomes in tumor tissue
is an important premise for successful therapies. Although the
size and PEGylation of liposomes have realized the sufficient
delivery to tumor, drug release has to be triggered by either
inner stimulations such as changes of pH and oxygen level, or
outer stimulations such as the local heating. Thermosensitive
liposome is a new kind of liposomal formulation, which can
immediately release encapsulated drugs in the tumor region
with local heating owing to the gel-to-liquid crystalline phase
change of lipids used to construct the formulation. This strat-
egy has already been applied to the next generation of
doxorubicin-loaded liposomal product, called ThermoDox.
DPPC and MSPC are key lipid components of ThermoDox. The
Tm of DPPC is 41.5 C, ensuring a phase change at about 42 C, a
clinically attainable temperature for local hyperthermia [59].
However, the drug release was still relatively slow for lipo-
somes composed of DPPC alone. So, the addition of small
amount of MSPC, a kind of lysolipid inducing a slight decrease
of Tm but the significant instability of lipid membrane at Tm,
could further accelerate drug release [67]. In a previous study
using local hyperthermia, ThermoDox was found to achieve
higher concentration of doxorubicin in tumor as well as
stronger anti-tumor effect than non-thermosensitive lipo-
somes [36]. There is an ongoing Phase III trial for the treatment
of hepatocellular carcinoma with ThermoDox [68].
3.3.2. Liposomal combinations in cancer therapy
Combination chemotherapy, i.e. the use of drugs with
different mechanisms of action and non-overlapping side ef-
fects, appears promising in the treatment of malignant cancer
and has also been applied to the development of nano-
medicines. Two sets of liposomal drug combinations have
entered clinical trials. CPX-351 is the liposome product co-
encapsulating cytarabine and daunorubicin in a molar ratio
of 5:1 for leukemia therapy. This combination ratio was found
to achieve the greatest degree of synergy in a panel of 15
tumor cell lines as well as 3 animal models [69]. The
maximum tolerated dose and the lowest response dose for the
combination have been determined in a completed Phase I
trial and there is a Phase II trial ongoing [54].
Another product entering Phase II trial is CPX-1 in which
irinotecanHCl and floxuridine are co-encapsulated at 1:1molar
ratio. The liposomal drug combination achieved better
response rate (7.7%) and progression-free-survival (3.9months)
than either floxuridine (4%, 2.5 months) or irinotecan (4.2%, 2.6
months) alone for the treatment of advanced colorectal cancer;
while theadverseeffectswere similar to thoseof irinotecan [55].
3.3.3. Liposomal vaccines
Liposomal vaccines, also known as virosomes [70], are con-
structedwith viral surface antigens and synthetic lipids such as
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cine delivery. Comparedwith conventional vaccines, virosomes
exhibit the excellent immunogenicity as well as better biocom-
patibility and safety. To date, two liposomal vaccines, Epaxal
and Inflexal V, have been approved for clinical use.
Epaxal is a hepatitis A virus (HAV) vaccine. In a clinical
study, the efficacy of Epaxal was comparedwith a conventional
HAV vaccine in infants and children. The seroprotection rate
was 100% in all participants after primary vaccination with
Epaxal. In conventional vaccine treatment groups, this rate
dropped to 67.7% in infants with pre-existing maternal anti-
HAV antibodies [71]. Due to the absence of aluminum, which
was widely used in conventional HAV vaccines, there were
fewer local reactions and side effects caused by Epaxal [72].
Inflexal V is an influenza vaccine which has been used
worldwide for fifteen years. In a clinical study involving 453
children, Inflexal V achieved a significantly higher seropro-
tection rate (88.8%) for H3N2 virus than that of a conventional
influenza vaccine (78.3%), indicating the better immunoge-
nicity [73]. Moreover, the superior purity and biocompatible
nature of Inflexal V constituents resulted in a significantly
reduced rate of unwanted side effects [74].
Liposomal vaccines are also investigated in cancer treat-
ment currently. Stimuvax containing BLP25 lipopeptide is a
cancer vaccine that targets the MUC1 tumor-associated anti-
gen [75]. In Phase II studies, the 3-year survival rate of patients
with non-small-cell carcinoma was 31% for the Stimuvax
treatment group and 17% for the control group [76]. No severe
toxicities were observed during Stimuvax treatment [77].
Recently, there began a further Phase III study on Stimuvax for
the stage III non-small-cell carcinoma [50].4. Conclusion
Discovered in 1965, liposomal formulations have been inves-
tigated for almosthalf a century. The successfulDoxil,which is
thefirst approved liposomalproduct,has inspiredexplorations
for new liposome delivery systems and brought about various
products as well as numerous clinical trials. Conventional
chemotherapeutic drugs, such as doxorubicin, paclitaxel and
cisplatin, have been developedwith liposomal formulations in
order to improve efficacy, and more importantly to reduce
toxicities. Besides, new technology has continuously been
applied to the formulation development process. For example,
PEGylation used in Doxil has significantly prolonged the in vivo
circulation time and improved the tumor delivery; DSPC used
in Lipo-dox has enhanced the formulation stability; and DPPC
used in ThermoDox has realized a stimulative drug release in
tumor with local heating strategy. Moreover, newly developed
liposomal combinations and liposomal vaccines have shown
promising results in clinical studies. In all, liposomal formu-
lations are still important and successful accesses for the
clinical application of nanomedicines.
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